Fresenius Medical Care Deutschland Gmbh

Unicyte Ev Ag

Presenius Medical Care Deutschland Gmbh

Usicyte Ev Ag

Evobiotech S.r.l. in Liquidazione

Giovanni Camussi

Ciro Tetta

Maria Beatriz Herrera Sanchez

Valentina Fonsato

Maria Felice Brizzi

Benedetta Bussolati

Stefania Bruno

Maria Chiara Deregibus

Vincenzo Cantaluppi

Sara Giunti

Andrea Ranghino

Victor Manuel Navarro Tableros

Paul Robbins

Tatiana Lopatina

Stefano Buttiglieri

Ilaria Deambrosis

Federico Figliolini

Margherita Alba Carlotta Pomatto

Chiara Gai

Claudia Cavallari

Veronica Dimuccio

Maria Chiara Amilde Deregibus

There is disclosed a preparation of extracellular vesicles derived from human liver stem cells, preferably from a non-oval human progenitor cell line that expresses hepatic cell markers, which is capable of reducing the senescence of a population of senescent cells, as measured in a SA-β-galactosidase-based cellular senescence assay. Also disclosed are therapeutic applications of the preparation of extracellular vesicles derived from human liver stem cells according to the invention. Therapeutic applications include the reduction of cellular senescence, e.g. in an vitro or ex vivo method, as well as the therapeutic treatment of diseases and conditions known to be related to ageing and cellular senescence, such as for example atherosclerosis, diabetes mellitus type 2, asthenia, and others.

Extracellular vesicles derived from human liver stem cells (HLSCs)

The present invention relates to compositions of extracellular vesicles (EVs) which are characterized by a strong proangiogenic activity and are effective in the therapeutic treatment of ischemic diseases and ischemic injuries or in wound healing. The extracellular vesicles (EVs) suitable for use in the compositions of the invention are either derived from a blood component or are selected by means of a potency test for pro-angiogenesis. Also disclosed is a method of manufacturing a pharmaceutical preparation of extracellular vesicles (EVs) characterized by a strong proangiogenic activity.

Composition of extracellular vesicles (EVS) and medical uses thereof

The invention relates to compositions and methods for isolating extracellular vesicles (EVs) from a biological fluid sample. The compositions and methods of the invention are based on the combination of a polycation with an extracellular matrix forming polymer. Extracellular vesicles (EVs) are isolated from biological fluids such as blood, serum, plasma, saliva, urine or cerebrospinal fluid, or from the conditioned medium of a cell culture, such as an adult stem cell culture. The use of the isolation methods and compositions of the invention results in a higher EVs recovery, enrichment in exosomes, simplicity, cost-effectiveness, and in the isolation of EVs that retain their biological activities in vitro.

Isolation of extracellular vesicles (EVs) from biological fluid samples

The invention relates to a method of preparing pancreatic islet-like cell structures characterized by a unique combination of morphological and functional features which make them particularly suitable for use in both clinical and drug screening application, as well as to the pancreatic islet-like cell structures obtained therefrom.

Pancreatic islet-like cell structures and a method of preparing thereof

A method for treating renal cancer by administering a pharmaceutically acceptable carrier comprising a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof is provided. In an embodiment, the pharmaceutically acceptable carrier is an extracellular vesicle (EV) derived from an adult stem cell selected from the group consisting of a mesenchymal stem cell (MSC), a non-oval human liver progenitor cell (HLSC) and an adipose stem cell (ASC).

Pharmaceutical carriers containing miRNAs for use in the treatment of renal cancer

The invention relates to a new therapeutic application of pharmaceutically acceptable carriers containing miR222. In particular, the invention relates to the use of extracellular vesicles (EVs) which contain the microRNA miR222, in the treatment of fibrotic disease caused by hyperglycaemia, such as diabetic nephropathy and/or renal fibrosis.

Pharmaceutical carriers containing miRNAs for use in the treatment of fibrotic diseases caused by hyperglycemia

The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.

Conditioned medium of liver progenitor cells

The invention is in the field of therapeutic treatment of tumors. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumor effect when administered to a patient affected by a tumor disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.

Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease

Microvesicles (MVS) derived from adult stem cells for use in the therapeutic treatment of a tumor disease

The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterized by the marker profile CD133, CD146, CD34and CD105. A method of preparing the hGL-MSC of the invention form decapsulated glomeruli is also disclosed, as well as the uses of the hGL-MSC of the invention in the regenerative treatment of the kidney, particularly for the treatment of injuries or diseases affecting renal glomeruli.

Isolated multipotent mesenchymal stem cell from human adult glomeruli (HGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney

The invention relates to human liver pluripotent progenitor cell lines which express hepatic cell markers such as albumin and &#x3b1;-fetoprotein and do not express some of the markers which are typical of oval stem cells. Also disclosed is a method of isolating the cell lines of the invention, methods for differentiating said cells into a plurality of different cell lineages, methods for conditional immortalization and metabolic selection of said cells, as well as the use of the cell lines of the invention for preparing a medicament with osteogenic differentiation activity or liver injury regeneration activity.

Growing community of inventors

Turin, Italy

Giovanni Camussi